8-K: Apogee Therapeutics Announces Positive Phase 1b Results for APG808 in Asthma, Reports Q1 2025 Financials

Apogee Therapeutics reports positive interim Phase 1b results for APG808 in mild-to-moderate asthma, demonstrating rapid and sustained suppression of FeNO, and provides a business update and Q1 2025 financial results.

Summary

• Apogee Therapeutics announced positive interim results from its Phase 1b trial of APG808 in patients with mild-to-moderate asthma.
• The trial demonstrated that APG808 was well-tolerated and resulted in rapid and sustained suppression of FeNO, a biomarker of Type 2 inflammation.
• The company believes APG808 has the potential for 2-month or longer maintenance dosing, offering an advantage over the current bi-weekly standard of care.
• Apogee also reported first quarter 2025 financial results, with $681.4 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q1 2028.
• The company's pipeline is progressing, with the Phase 2 APEX trial of APG777 in atopic dermatitis advancing and a Phase 1b trial of APG777 in mild-to-moderate asthma initiated.
• A head-to-head Phase 1b study of APG279 versus DUPIXENT in AD is planned for 2025.
• R&D expenses for the quarter ended March 31, 2025, were $46.4 million, compared to $28.7 million for the same period in 2024.
• G&A expenses for the quarter ended March 31, 2025, were $16.7 million, compared to $9.5 million for the same period in 2024.
• The net loss for the quarter ended March 31, 2025, was $55.3 million, compared to a net loss of $32.1 million for the quarter ended March 31, 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a strong financial position, indicating a favorable outlook for the company. The positive market research and potential for differentiated dosing contribute to the positive sentiment.

Positives

• APG808 demonstrated a favorable safety profile in the Phase 1b trial.
• APG808 showed rapid and durable suppression of FeNO, a key biomarker in asthma.
• The company has a strong cash position to fund operations into Q1 2028.
• Market research indicates strong preference for APG777's quarterly dosing profile over existing biologics and hypothetical daily orals.
• The AD biologic market is experiencing rapid growth, with year-to-date growth of 23% in total prescriptions and 44% in new-to-brand prescriptions.

Negatives

• The company reported a net loss of $55.3 million for the quarter ended March 31, 2025, which is higher than the net loss of $32.1 million for the same period in 2024.
• Increased R&D and G&A expenses contributed to the higher net loss.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties, including those related to clinical trial outcomes, regulatory approvals, and macroeconomic conditions.
• The relationship between preclinical study results and clinical study results is unpredictable.
• The timing or likelihood of regulatory filings and approvals is uncertain.

Future Outlook

Apogee anticipates multiple catalysts across its portfolio in the months ahead and expects an exciting and productive 2025 and 2026, with a strong cash position supporting operations into Q1 2028.

Management Comments

• 2025 is poised to be a transformational year for Apogee, and we are pleased with the strong execution in the first quarter as we continue to advance therapies with the goal of reshaping the standard of care for patients living with I&I diseases, said Michael Henderson, M.D., Chief Executive Officer of Apogee.
• With its potential best-in-class PK profile, APG808 could substantially improve clinical outcomes for patients with asthma over the biweekly current standard of care and enable dosing as infrequently as every two months or longer, said Michael Henderson, M.D., Chief Executive Officer of Apogee.
• Based on the recent market research we commissioned, APG777s potential quarterly dosing is highly preferred by both physicians and patients to other available options, said Jeff Hartness, Chief Commercial Officer of Apogee.
• Physicians expressed strong interest in both initiating new-to-biologic patients to APG777 as well as switching patients already on biologics to APG777, assuming comparable efficacy and safety to current biologics, said Jeff Hartness, Chief Commercial Officer of Apogee.

Industry Context

Apogee is positioning itself to compete in the rapidly expanding inflammatory and immunology (I&I) market, particularly in atopic dermatitis and asthma, by developing novel biologics with differentiated efficacy and dosing compared to existing therapies like DUPIXENT.

Comparison to Industry Standards

• APG808's preclinical studies showed similar binding and femtomolar affinity for IL-4R compared to DUPIXENT.
• APG808 demonstrated similar inhibition to DUPIXENT in preclinical studies.
• APG808 showed greater mean FeNO reduction relative to DUPIXENT in the Phase 1b trial.
• APG808's TARC suppression was similar to DUPIXENT.
• The company is aiming for best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies, potentially offering less frequent dosing schedules than current standards.

Stakeholder Impact

• Shareholders: Positive clinical trial results and strong financial position could lead to increased stock value.
• Patients: Potential for improved treatment options with differentiated efficacy and dosing.
• Employees: Company growth and pipeline advancement could lead to increased job security and opportunities.

Next Steps

• The company expects to report 16-week topline data from Part A of the Phase 2 APEX trial in mid-2025 and from Part B in the second half of 2026.
• Apogee plans to initiate its first-in-class combination trial, a Phase 1b trial designed to evaluate the safety, PK, pharmacodynamics and efficacy of APG279 against DUPIXENT in patients with moderate-to-severe AD this year, with an interim readout expected in the second half of 2026.
• A Phase 1 trial of APG333 in healthy volunteers is underway, with data expected in the second half of 2025.
• The company expects to report readout from Phase 1b trial of APG777 in mild-to-moderate asthma in 1H 2026.
• The company also plans to initiate a Phase 2 trial in EoE in 2026.

Key Dates

Keywords

APG808, APG777, Apogee Therapeutics, Asthma, Atopic Dermatitis, FeNO, Clinical Trial, Biologics, Phase 1b, Phase 2, Financial Results, R&D Expenses, IL-4R, DUPIXENT, Inflammation, Immunology